News & Updates

In Japan, the declaration of a state of emergency in response to the COVID-19 pandemic led to negative metabolic consequences in people with glucose intolerance, such as lowered skeletal muscle and increased body weight and body fat, a recent study has found.

All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.

Patients immunized with the influenza vaccine see significant protection against mechanical ventilation in COVID-19, a recent study has found.

Psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, are common among cancer patients during the COVID-19 pandemic, as were fears of disease progression or recurrence, a recent study has found.

The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.

There is inconclusive evidence that wearing one’s eyeglasses can lower their chances of contracting COVID-19, according to a recent study.

Poor health-related quality of life (HRQoL), along with high levels of anxiety and other mental health problems, has become more common among children and adolescents during the COVID-19 pandemic, according to a recent German study.

In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.